Publicaciones en colaboración con investigadores/as de Hospital del Mar (20)

2024

  1. Prognostic value of response to first-line hydroxyurea according to IPSET stratification in essential thrombocythemia

    Leukemia

2022

  1. A randomized phase II study comparing consolidation with a single dose of 90Y ibritumomab tiuxetan vs. maintenance with rituximab for two years in patients with newly diagnosed follicular lymphoma responding to R-CHOP. Long-term follow-up results

    Leukemia and Lymphoma, Vol. 63, Núm. 1, pp. 93-100

  2. IBRORS-MCL study: a Spanish retrospective and observational study of relapsed/refractory mantle-cell lymphoma treated with ibrutinib in routine clinical practice

    International Journal of Hematology, Vol. 116, Núm. 3, pp. 381-392

  3. Real-world study of children and young adults with myeloproliferative neoplasms: identifying risks and unmet needs

    Blood Advances, Vol. 6, Núm. 17, pp. 5171-5183

2021

  1. The risk of thrombosis in essential thrombocythemia is associated with the type of CALR mutation: A multicentre collaborative study

    European Journal of Haematology, Vol. 106, Núm. 3, pp. 371-379

2020

  1. RELINF: prospective epidemiological registry of lymphoid neoplasms in Spain. A project from the GELTAMO group

    Annals of Hematology, Vol. 99, Núm. 4, pp. 799-808

2019

  1. Management of adult patients with primary immune thrombocytopenia (itp) in clinical practice: A consensus approach of the Spanish itp expert group

    Advances in Hematology, Vol. 2019

  2. The poor prognosis of low hypodiploidy in adults with B-cell precursor acute lymphoblastic leukaemia is restricted to older adults and elderly patients

    British Journal of Haematology, Vol. 186, Núm. 2, pp. 263-268

2017

  1. Clinical outcomes of 217 patients with acute erythroleukemia according to treatment type and line: A retrospective multinational study

    International Journal of Molecular Sciences, Vol. 18, Núm. 4

  2. Predictive factors for anemia response to erythropoiesis-stimulating agents in myelofibrosis

    European Journal of Haematology, Vol. 98, Núm. 4, pp. 407-414

  3. Progression-free survival at 2 years post-autologous transplant: a surrogate end point for overall survival in follicular lymphoma

    Cancer Medicine, Vol. 6, Núm. 12, pp. 2766-2774

  4. Risk of thrombosis according to need of phlebotomies in patients with polycythemia vera treated with hydroxyurea

    Haematologica, Vol. 102, Núm. 1, pp. 103-109

2016

  1. Recommendations on the clinical use of bendamustine in lymphoproliferative syndromes and multiple myeloma

    European Journal of Haematology, Vol. 96, Núm. 5, pp. 532-540

2015

  1. Azacitidine frontline therapy for unfit acute myeloid leukemia patients: Clinical use and outcome prediction

    Leukemia Research, Vol. 39, Núm. 3, pp. 296-306

  2. Bosutinib shows low cross intolerance, in chronic myeloid leukemia patients treated in fourth line. Results of the Spanish compassionate use program

    American Journal of Hematology, Vol. 90, Núm. 5, pp. 429-433

2013

  1. Application of FISH 7q in MDS patients without monosomy 7 or 7q deletion by conventional G-banding cytogenetics: Does -7/7q- detection by FISH have prognostic value?

    Leukemia Research, Vol. 37, Núm. 4, pp. 416-421

2010

  1. Clinical significance of occult cerebrospinal fluid involvement assessed by flow cytometry in non-Hodgkin's lymphoma patients at high risk of central nervous system disease in the rituximab era

    European Journal of Haematology, Vol. 85, Núm. 4, pp. 321-328

2009

  1. Efficacy and safety of Liposomal cytarabine in lymphoma Patients with central nervous system involvement from lymphoma

    Cancer, Vol. 115, Núm. 9, pp. 1892-1898

2008

  1. R-ESHAP as salvage therapy for patients with relapsed or refractory diffuse large B-cell lymphoma: The influence of prior exposure to rituximab on outcome. A GEL/TAMO study

    Haematologica, Vol. 93, Núm. 12, pp. 1829-1836

2007

  1. Results of the PETHEMA ALL-96 trial in elderly patients with Philadelphia chromosome-negative acute lymphoblastic leukemia

    European Journal of Haematology, Vol. 78, Núm. 2, pp. 102-110